Prevalence of Human Papillomavirus and Estimation of Human Papillomavirus Vaccine Effectiveness in Thimphu, Bhutan, in 2011–2012 and 2018

2020 ◽  
Vol 173 (11) ◽  
pp. 888-894 ◽  
Author(s):  
Iacopo Baussano ◽  
Ugyen Tshomo ◽  
Vanessa Tenet ◽  
Daniëlle A.M. Heideman ◽  
Tshering Wangden ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine

scholarly journals Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses

2019 ◽  
Vol 221 (6) ◽  
pp. 910-918 ◽  
Author(s):  
Lauri E Markowitz ◽  
Allison L Naleway ◽  
Nicola P Klein ◽  
Rayleen M Lewis ◽  
Brad Crane ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Hpv Vaccine ◽  
Hpv Infection ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
Specimen Collection ◽  
National Programs ◽  
Collection Date ◽  
Papillomavirus Vaccine ◽  
Prevalence Ratios

Abstract Background Highly effective human papillomavirus (HPV) vaccines are used in many national programs in 3- or 2-dose schedules. We examined HPV vaccine effectiveness against HPV prevalence by number of doses. Methods We collected residual liquid-based cytology samples from US women aged 20–29 years who were screened for cervical cancer. Women continuously enrolled from 2006 through the specimen collection date were analyzed. Specimens were tested using the Linear Array assay. We analyzed prevalence of quadrivalent HPV vaccine (4vHPV) types (HPV 6,11,16,18) and other HPV-type categories and determined prevalence ratios (PRs) and 95% confidence intervals (CIs) for 1, 2, and 3 compared with no vaccine doses. Results Among 4269 women, 1052 (24.6%) were unvaccinated, 2610 (61.1%) received 3 doses, 304 (7.1%) received 2 doses, and 303 (7.1%) received 1 dose. The 4vHPV-type prevalence was 7.4% among unvaccinated women compared with 1.7%, 1.0%, and 1.0% among 1-, 2-, and 3-dose recipients. Among women vaccinated at ≤18 years, adjusted PRs for 1, 2, and 3 doses were 0.06 (95% CI, 0.01–0.42), 0.05 (95% CI, 0.01–0.39), and 0.06 (95% CI, 0.04–0.12). Conclusions Among women who received their first dose at age ≤18, estimated HPV vaccine effectiveness was high regardless of number of doses.

scholarly journals Human Papillomavirus Vaccine Effectiveness Against Incident Genital Warts Among Female Health-Plan Enrollees, United States

2017 ◽  
Vol 187 (2) ◽  
pp. 298-305 ◽  
Author(s):  
Susan Hariri ◽  
Megan S Schuler ◽  
Allison L Naleway ◽  
Matthew F Daley ◽  
Sheila Weinmann ◽  
...  
Keyword(s):  
United States ◽  
Human Papillomavirus ◽  
Health Plan ◽  
Genital Warts ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
Papillomavirus Vaccine

scholarly journals Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study

2013 ◽  
Vol 105 (7) ◽  
pp. 469-474 ◽  
Author(s):  
Amy Leval ◽  
Eva Herweijer ◽  
Alexander Ploner ◽  
Sandra Eloranta ◽  
Julia Fridman Simard ◽  
...  
Keyword(s):  
Cohort Study ◽  
Human Papillomavirus ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
National Cohort ◽  
Papillomavirus Vaccine

scholarly journals Human Papillomavirus Vaccine Effectiveness and Herd Protection in Young Women

PEDIATRICS ◽  
2019 ◽  
Vol 143 (2) ◽  
pp. e20181902 ◽  
Author(s):  
Chelse Spinner ◽  
Lili Ding ◽  
David I. Bernstein ◽  
Darron R. Brown ◽  
Eduardo L. Franco ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Young Women ◽  
Vaccine Effectiveness ◽  
Human Papillomavirus Vaccine ◽  
Herd Protection ◽  
Papillomavirus Vaccine
Sign in / Sign up

Export Citation Format

Share Document